Next Article in Journal
The Importance of Endophenotypes to Evaluate the Relationship between Genotype and External Phenotype
Next Article in Special Issue
Exosomes: From Garbage Bins to Promising Therapeutic Targets
Previous Article in Journal
An Automated Micro-Total Immunoassay System for Measuring Cancer-Associated α2,3-linked Sialyl N-Glycan-Carrying Prostate-Specific Antigen May Improve the Accuracy of Prostate Cancer Diagnosis
Previous Article in Special Issue
MicroRNAs: New Insight in Modulating Follicular Atresia: A Review
Review

Current Insights into Long Non-Coding RNAs (LncRNAs) in Prostate Cancer

1
Division of Clinical Oncology, Internal Medicine, Medical University of Graz, Auenbruggerplatz 15, A-8036 Graz, Austria
2
Department of Orthopaedic and Trauma Surgery, Medical University of Graz, Auenbruggerplatz 5, A-8036 Graz, Austria
3
Department of Urology, Medical University of Graz, Auenbruggerplatz 5/6, A-8036 Graz, Austria
4
Department of Experimental Therapeutics, The University of Texas MD Anderson Cancer, 1515 Holcombe Blvd., Houston, TX 77030, USA
5
Center for RNA Interference and Non-Coding RNAs, The University of Texas MD Anderson Cancer Center, 1515 Holcombe Blvd., Houston, TX 77030, USA
*
Author to whom correspondence should be addressed.
Academic Editor: Constantinos Stathopoulos
Int. J. Mol. Sci. 2017, 18(2), 473; https://0-doi-org.brum.beds.ac.uk/10.3390/ijms18020473
Received: 16 January 2017 / Revised: 9 February 2017 / Accepted: 16 February 2017 / Published: 22 February 2017
(This article belongs to the Collection Regulation by Non-Coding RNAs)
The importance of long non-coding RNAs (lncRNAs) in the pathogenesis of various malignancies has been uncovered over the last few years. Their dysregulation often contributes to or is a result of tumour progression. In prostate cancer, the most common malignancy in men, lncRNAs can promote castration resistance, cell proliferation, invasion, and metastatic spread. Expression patterns of lncRNAs often change during tumour progression; their expression levels may constantly rise (e.g., HOX transcript antisense RNA, HOTAIR), or steadily decrease (e.g., downregulated RNA in cancer, DRAIC). In prostate cancer, lncRNAs likewise have diagnostic (e.g., prostate cancer antigen 3, PCA3), prognostic (e.g., second chromosome locus associated with prostate-1, SChLAP1), and predictive (e.g., metastasis-associated lung adenocarcinoma transcript-1, MALAT-1) functions. Considering their dynamic role in prostate cancer, lncRNAs may also serve as therapeutic targets, helping to prevent development of castration resistance, maintain stable disease, and prohibit metastatic spread. View Full-Text
Keywords: long non-coding RNAs; prostate cancer; carcinogenesis long non-coding RNAs; prostate cancer; carcinogenesis
Show Figures

Figure 1

MDPI and ACS Style

Smolle, M.A.; Bauernhofer, T.; Pummer, K.; Calin, G.A.; Pichler, M. Current Insights into Long Non-Coding RNAs (LncRNAs) in Prostate Cancer. Int. J. Mol. Sci. 2017, 18, 473. https://0-doi-org.brum.beds.ac.uk/10.3390/ijms18020473

AMA Style

Smolle MA, Bauernhofer T, Pummer K, Calin GA, Pichler M. Current Insights into Long Non-Coding RNAs (LncRNAs) in Prostate Cancer. International Journal of Molecular Sciences. 2017; 18(2):473. https://0-doi-org.brum.beds.ac.uk/10.3390/ijms18020473

Chicago/Turabian Style

Smolle, Maria A., Thomas Bauernhofer, Karl Pummer, George A. Calin, and Martin Pichler. 2017. "Current Insights into Long Non-Coding RNAs (LncRNAs) in Prostate Cancer" International Journal of Molecular Sciences 18, no. 2: 473. https://0-doi-org.brum.beds.ac.uk/10.3390/ijms18020473

Find Other Styles
Note that from the first issue of 2016, MDPI journals use article numbers instead of page numbers. See further details here.

Article Access Map by Country/Region

1
Back to TopTop